Vitamin k for prevention and treatment of skin rash secondary to anti-egfr therapy

Abstract

The invention provides methods and compositions for treating and preventing a skin rash secondary to anti-epidermal growth factor receptor (EGFR) therapy, where the method comprises applying a vitamin K analog or a phosphatase inhibitor to the skin.

1 - 27 . (canceled) 
     
     
         28 . A pharmaceutical composition comprising an amount of a vitamin K3 effective to treat or prevent a skin rash secondary to an anti-epidermal growth factor receptor (EGFR) therapy. 
     
     
         29 - 41 . (canceled) 
     
     
         42 . A method for treating or preventing a skin or mucosal ulceration in a subject, the method comprising applying to the skin or mucosal ulceration an amount of a vitamin K1 or vitamin K3 effective to treat the skin or mucosal ulceration. 
     
     
         43 . The method of  claim 42 , wherein the skin or mucosal ulceration is ulcerative colitis, chemotherapy-induced oral mucosistis, or radiotherapy-induced oral mucosistis. 
     
     
         44 - 45 . (canceled) 
     
     
         46 . The method of  claim 42 , wherein vitamin K3 is applied to the skin or mucosal ulceration at a concentration of at least 15 μg/ml. 
     
     
         47 . The method of  claim 42 , wherein vitamin K3 is applied to the skin or mucosal ulceration at a concentration of 75 μg/ml to 100 μg/ml. 
     
     
         48 . The method of  claim 42 , wherein vitamin K1 is applied to the skin or mucosal ulceration at a concentration of at least 450 μg/ml. 
     
     
         49 . A method for treating or preventing a skin rash secondary to an anti-epidermal growth factor receptor (EGFR) therapy in a subject receiving said therapy, the method comprising applying a phosphatase inhibitor to the skin rash in an amount effective to treat the skin rash. 
     
     
         50 - 65 . (canceled) 
     
     
         66 . A pharmaceutical composition comprising an amount of a phosphatase inhibitor effective to treat or prevent a skin rash secondary to an anti-epidermal growth factor receptor (EGFR) therapy. 
     
     
         67 - 69 . (canceled) 
     
     
         70 . A method for treating or preventing a skin or mucosal ulceration in a subject, the method comprising applying to the skin or mucosal ulceration an amount of a phosphatase inhibitor effective to treat the skin or mucosal ulceration, wherein the phosphatase inhibitor inhibits dephosphorylation of EGFR. 
     
     
         71 . (canceled) 
     
     
         72 . The method of  claim 42 , wherein the vitamin K1 or vitamin K3 is formulated in a pharmaceutical formulation suitable for topical administration.